Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemoglobin e syndromes.

Elliott Vichinsky1

  • 1Children's Hospital and Research Center Oakland, 747 52nd Street, Oakland, CA 94609, USA. evichinsky@mail.cho.org

Hematology. American Society of Hematology. Education Program
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hospital Variations in Time-To-Crisis-Resolution Among Children and Adolescents With Sickle Cell Disease.

American journal of hematology·2025
Same author

Diagnosis and Treatment of Alpha Thalassemia Major.

Hemoglobin·2025
Same author

Disease burden, management strategies, and unmet needs in α-thalassemia due to hemoglobin H disease.

American journal of hematology·2024
Same author

COVID-19 mRNA vaccination responses in individuals with sickle cell disease: an ASH RC Sickle Cell Research Network Study.

Blood advances·2024
Same author

Neurocognitive outcome in children with sickle cell disease after myeloimmunoablative conditioning and haploidentical hematopoietic stem cell transplantation: a non-randomized clinical trial.

Frontiers in neurology·2024
Same author

Improving healthspan among people with sickle cell disease: Leveraging precision health in an era of treatments with curative intent.

American journal of hematology·2024
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Hemoglobin E disorders vary widely, from mild to severe E beta-thalassemia. Understanding genotypes and modifiers is crucial for managing complications like iron overload and pulmonary hypertension.

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Hemoglobin (Hb) E is a prevalent mutation causing diverse blood disorders.
  • Phenotypes range from asymptomatic Hb E trait to severe E beta-thalassemia.
  • Accurate diagnosis is vital due to significant clinical course differences.

Purpose of the Study:

  • To highlight the diagnostic challenges and clinical variability of Hb E disorders.
  • To discuss the impact of genetic and environmental modifiers on E beta-thalassemia.
  • To review complications and therapeutic strategies for E beta-thalassemia.

Main Methods:

  • Review of existing literature on Hemoglobin E disorders.
  • Analysis of diagnostic screening methods like HPLC and electrophoresis.

Related Experiment Videos

  • Prospective natural history study data from Sri Lanka on E beta-thalassemia.

    • Main Results:

    • Hb E disorders present a spectrum from mild (Hb E trait, Hb EE) to severe (E beta-thalassemia).
    • E beta-thalassemia, affecting a million globally, shows significant phenotypic variability.
    • Complications include iron overload, thromboembolism, and cardiopulmonary disease.
    • Environmental factors and genetic modifiers influence prognosis.
    • Hydroxyurea shows potential, with 40% of patients improving.

    Conclusions:

    • Distinguishing Hb E genotypes is critical for appropriate patient management.
    • E beta-thalassemia requires comprehensive monitoring for acute and chronic complications.
    • Hb F-modulating agents, like hydroxyurea, offer therapeutic promise.